NCT05952986View on ClinicalTrials.gov

A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults

PHASE1UnknownINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

May 3, 2023

Primary Completion Date

March 26, 2024

Study Completion Date

March 26, 2024

Conditions
Atopic Dermatitis
Interventions
DRUG

FB825 or Placebo in subcutaneous route

FB825 or placebo solution for SC injection

DRUG

FB825 in intravenous route

FB825 solution for IV infusion

Trial Locations (1)

92801

Phase I center, Anaheim

Sponsors
All Listed Sponsors
lead

Oneness Biotech Co., Ltd.

INDUSTRY